Choose Your Country or Region

Anti-CX3CL1/Fractalkine Chemokine Domain Rat Antibody [K3M15]

Catalog No.: F3830

Application: Reactivity: Mouse

Usage Information

Dilution
WB1:2000

Application
WB, ELISA

Reactivity
Mouse

Source
Rat

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Datasheet & SDS

Biological Description

Specificity
CX3CL1/Fractalkine Chemokine Domain Mouse mAb detects endogenous levels of total CX3CL1/Fractalkine Chemokine Domain protein.

Subcellular Location
Cell membrane, Membrane, Secreted

Uniprot ID
P78423

Clone
K3M15

Synonym(s)
ABCD-3; C3Xkine; chemokine (C-X3-C motif) ligand 1; CX3C membrane-anchored chemokine; CX3CL1; CXC3; CXC3C; FKN; Fractalkine; Neurotactin; neurotactin); NTNsmall inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine; NTTSmall-inducible cytokine D1; SCYD1C-X3-C motif chemokine 1; small inducible cytokine subfamily D (Cys-X3-Cys), member-

Background
CX3CL1, also known as fractalkine, is the only member of the CX3C chemokine family and is distinguished by three amino acids separating its first two conserved cysteine residues. It is synthesized as a 373-amino acid type I transmembrane protein consisting of four major domains: an N-terminal chemokine domain that mediates chemoattraction, a mucin-like stalk that supports cell adhesion, a transmembrane segment that anchors the protein to the cell surface, and a cytoplasmic domain involved in intracellular signaling. Fractalkine uniquely exhibits both chemotactic and adhesive properties, acting as a membrane-bound adhesion molecule and, upon cleavage by metalloproteinases ADAM10 and ADAM17, functioning as a soluble chemoattractant. Its receptor, CX3CR1, is a G protein-coupled receptor expressed on immune and vascular cells, including monocytes, macrophages, NK cells, T cells, and smooth muscle cells. The binding of CX3CL1 to CX3CR1 activates multiple signaling pathways, including PI3K, MAPK, AKT, Src, and eNOS, which regulate immune cell adhesion, migration, survival, and resistance to apoptosis. The CX3CL1–CX3CR1 axis is involved in key physiological processes such as immune surveillance, angiogenesis, and tissue repair, while also contributing to the pathogenesis of conditions like atherosclerosis, cancer, and neuroinflammation by promoting inflammatory cell recruitment and vascular dysfunction. Genetic variants in CX3CR1 can alter receptor activity and influence individual susceptibility to inflammatory and degenerative diseases.

Background

CX3CL1, also known as fractalkine, is the only member of the CX3C chemokine family and is distinguished by three amino acids separating its first two conserved cysteine residues. It is synthesized as a 373-amino acid type I transmembrane protein consisting of four major domains: an N-terminal chemokine domain that mediates chemoattraction, a mucin-like stalk that supports cell adhesion, a transmembrane segment that anchors the protein to the cell surface, and a cytoplasmic domain involved in intracellular signaling. Fractalkine uniquely exhibits both chemotactic and adhesive properties, acting as a membrane-bound adhesion molecule and, upon cleavage by metalloproteinases ADAM10 and ADAM17, functioning as a soluble chemoattractant. Its receptor, CX3CR1, is a G protein-coupled receptor expressed on immune and vascular cells, including monocytes, macrophages, NK cells, T cells, and smooth muscle cells. The binding of CX3CL1 to CX3CR1 activates multiple signaling pathways, including PI3K, MAPK, AKT, Src, and eNOS, which regulate immune cell adhesion, migration, survival, and resistance to apoptosis. The CX3CL1–CX3CR1 axis is involved in key physiological processes such as immune surveillance, angiogenesis, and tissue repair, while also contributing to the pathogenesis of conditions like atherosclerosis, cancer, and neuroinflammation by promoting inflammatory cell recruitment and vascular dysfunction. Genetic variants in CX3CR1 can alter receptor activity and influence individual susceptibility to inflammatory and degenerative diseases.

References
https://pubmed.ncbi.nlm.nih.gov/33391453/ https://pubmed.ncbi.nlm.nih.gov/24556958/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%